Investigator Initiated Study for the Safety and Efficacy in Frontotemporal Dementia

The purpose of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD), immunogenicity, and efficacy of multiple intravenous administrations of the investigational drug NS101, compared to placebo, in patients with semantic variant primary progressive aphasia (svPPA), a subtype of frontotemporal dementia (FTD)

NCT Number	NCT07154485
Lead Sponsor	Hee-Jin Kim Collaborators: Asan Medical Center, Gangnam Severance Hospital, Konkuk University Medical Center
Conditions	Dementia Frontotemporal
Enrollment	15 participants
Start Date	2025-10-01
Primary Completion	2027-08-01 (estimated)
Study Completion	2028-08-01 (estimated)
Updated on ClinicalTrials.gov	2025-09-04